Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SRTS 
Sensus Healthcare Inc (SRTS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SRTS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.4
1 Year Target Price $8.4
| 2 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.39% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 56.55M USD | Price to earnings Ratio - | 1Y Target Price 8.4 |
Price to earnings Ratio - | 1Y Target Price 8.4 | ||
Volume (30-day avg) 5 | Beta 1.35 | 52 Weeks Range 3.03 - 9.33 | Updated Date 08/15/2025 |
52 Weeks Range 3.03 - 9.33 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate 0.01 | Actual -0.06 |
Profitability
Profit Margin -2.26% | Operating Margin (TTM) 40.84% |
Management Effectiveness
Return on Assets (TTM) -1.46% | Return on Equity (TTM) -1.62% |
Valuation
Trailing PE - | Forward PE 44.64 | Enterprise Value 34986723 | Price to Sales(TTM) 1.51 |
Enterprise Value 34986723 | Price to Sales(TTM) 1.51 | ||
Enterprise Value to Revenue 0.93 | Enterprise Value to EBITDA 8.68 | Shares Outstanding 16440000 | Shares Floating 13857976 |
Shares Outstanding 16440000 | Shares Floating 13857976 | ||
Percent Insiders 16.97 | Percent Institutions 28.32 |
Upturn AI SWOT
Sensus Healthcare Inc
Company Overview
History and Background
Sensus Healthcare, Inc. was founded in 2010. It focuses on developing and marketing minimally invasive treatments for non-melanoma skin cancers and keloids.
Core Business Areas
- Superficial Radiation Therapy (SRT) Devices: Develops and sells SRT systems, primarily the SRT-100 Visionu2122, for treating non-melanoma skin cancers and keloids. These devices deliver precise doses of radiation to targeted areas.
- Services and Support: Provides ongoing service and support for its installed base of SRT devices, including maintenance, training, and software updates.
Leadership and Structure
Joe Sardano is the CEO of Sensus Healthcare. The company operates with a functional organizational structure, encompassing sales, marketing, research and development, and operations departments.
Top Products and Market Share
Key Offerings
- SRT-100 Visionu2122: The SRT-100 Visionu2122 is Sensus Healthcare's flagship product, used for superficial radiation therapy to treat non-melanoma skin cancers, keloids, and other skin conditions. Competitors include Accuray (ARAY) with their Radixact System, although SRT has the advantage of typically being done in a dermatologist office.
Market Dynamics
Industry Overview
The market for non-melanoma skin cancer treatment is growing due to increasing incidence rates and an aging population. Minimally invasive treatments are gaining popularity.
Positioning
Sensus Healthcare is positioned as a leader in SRT technology, offering a non-surgical alternative for treating skin cancers and keloids. Its competitive advantage lies in its specialized SRT systems and focused approach.
Total Addressable Market (TAM)
The total addressable market for non-melanoma skin cancer and keloid treatment is estimated in the billions of dollars globally. Sensus Healthcare is positioned to capture a segment of this market through its SRT technology.
Upturn SWOT Analysis
Strengths
- Proprietary SRT Technology
- Established Market Presence
- Strong Customer Relationships
- Focus on Niche Market
Weaknesses
- Limited Product Portfolio
- Reliance on Single Product Line
- Smaller Scale Compared to Larger Medical Device Companies
- Geographic concentration of sales in US
Opportunities
- Expanding into New Geographies
- Developing New Applications for SRT Technology
- Strategic Partnerships
- Increased Awareness of SRT Benefits
Threats
- Competition from Alternative Treatment Modalities
- Regulatory Changes
- Technological Advancements by Competitors
- Economic Downturns affecting Healthcare Spending
Competitors and Market Share
Key Competitors
- ARAY
Competitive Landscape
Sensus Healthcare competes with companies offering alternative skin cancer and keloid treatments, including surgical excision, radiation therapy, and topical medications. Sensus has the advantage of typically being done in a dermatologist office.
Growth Trajectory and Initiatives
Historical Growth: Sensus Healthcare's historical growth has been driven by the adoption of its SRT technology in dermatology and radiation oncology practices.
Future Projections: Future growth projections would depend on factors such as market penetration, new product development, and geographic expansion.
Recent Initiatives: Recent initiatives may include expanding sales and marketing efforts, developing new SRT applications, and pursuing regulatory approvals in new markets.
Summary
Sensus Healthcare is a niche player in the market for non-melanoma skin cancer and keloid treatments. Its SRT technology offers a non-surgical alternative, but it faces competition from other treatment modalities. Expanding into new markets and developing new applications for its technology will be crucial for future growth. Need more diversification of sales and a second major product.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, industry reports, market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sensus Healthcare Inc
Exchange NASDAQ | Headquaters Boca Raton, FL, United States | ||
IPO Launch date 2016-06-03 | Co-Founder, Chairman & CEO Mr. Joseph C. Sardano | ||
Sector Healthcare | Industry Medical Devices | Full time employees 54 | Website https://sensushealthcare.com |
Full time employees 54 | Website https://sensushealthcare.com | ||
Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, such as applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. The company was incorporated in 2010 and is based in Boca Raton, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.